(Q40163076)

English

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Riccardo Danielli

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Diana Giannarelli

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Ester Fonsatti

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Ornella Cutaia

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Carolina Fazio

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Diego Annesi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Marica Lenoci

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Giovanni Amato

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Maresa Altomonte

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Anna Maria Di Giacomo

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

publication date

26 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

301-309

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Advances in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multidisciplinary treatment of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line treatment for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

What's the place of immunotherapy in malignant mesothelioma treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New roads open up for implementing immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab: a review of development to date in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The value of inflammatory parameters in the prognosis of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900092-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(15)00092-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25819643%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40163076&oldid=1487139694"